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Abstract
Background: Icon is a novel, dual neovascular- and cancer cell-targeting immunotherapeutic agent and has
shown efficacy in the treatment of cancer, wet form macular degeneration and endometriosis. However, its
underlying mechanism remains to be investigated. The objective of this study is to elucidate the mechanism of
Icon immunotherapy in cancer using a squamous carcinoma human tongue cancer line TCA8113 in vitro and
in vivo in severe combined immunodeficiency (SCID) mice.
Results: We showed that Icon, as a chimeric factor VII and human IgG1 Fc immunoconjugate, could separately
induce murine natural killer (NK) cells and activate complement to kill TCA8113 cancer cells in vitro via antibody
dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). However, Icon-NK
ADCC had a significantly stronger effect than that of Icon-CDC. Moreover, Icon could completely eradicate
established human tongue tumour xenografts in vivo in the CB-17 strain of SCID mice that have functional NK cells
at a normal level, whereas it was less effective in SCID/Beige mice that do not have functional NK cells.
Conclusions: We conclude that NK cells are crucial for the efficacy of Icon immunotherapy in the treatment of
cancer. The results also suggest that impaired NK level/activity could contribute to the resistance to therapeutic
antibodies that are currently under investigation in preclinical and clinical studies.
Background
Several prevalent diseases such as cancer, exudative
(wet) age-related macular degeneration, diabetic retino-
pathy, and rheumatoid arthritis are associated with
abnormal angiogenesis, i.e., formation of pathological
neovasculature. It is believed that targeting pathological
neovasculature is a better strategy for cancer therapy
than targeting tumour cells [1]. In the case of cancer,
there are two methods for targeting pathological neovas-
culature in tumours, namely anti-angiogenesis by anti-
angiogenic inhibitors [2] and anti-neovasculature by
vascular disrupting agents [3-5]. Because pathological
neovasculature usually has formed by the time a diagno-
sis is reached, eradication of the pathological neovascu-
lature is necessary to achieve optimal therapeutic
efficacy. Among those vascular disrupting agents there
are several molecules called vascular targeting agents
[6]. These vascular targeting agents were designed to
bring soluble tissue factor (TF) to tumour endothelial
cells by targeting MHC class II, cell adhesion molecules,
fibronectin, or prostate specific membrane antigen, and
then to cause the shutdown of the blood vessels of
tumours by initiating blood clotting. The vascular tar-
geting agents are expected to show the greatest thera-
peutic benefit for anti-neovasculature treatment as part
of combined modality regimens [7].
The anti-pathological neovasculature protocol that
Garen and Hu developed [8-10] is different from anti-
angiogenic inhibitors and those TF-containing vascular
targeting agents. Our protocol is based on a chimeric
antibody-like molecule, named Icon, composed of two
mature coagulation factor VII (fVII) peptides, the nat-
ural ligand for receptor tissue factor (TF), fused to the
Fc domain of a human IgG1 antibody by recombinant
DNA technology. TF, a normal cell surface receptor
[11,12], is expressed on tumour vascular endothelial
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cells [13,14], which can be induced by tumour cell-pro-
duced VEGF and other growth factors [15,16], but not
on normal vascular endothelial cells [17-20]. Although
TF is expressed on extravascular cells of several normal
tissues and in the adventitial layer of the blood vessel
wall, it is sequestered by fVII at these sites by the tight
endothelial cell layer of the normal vasculature [17-19].
In addition, TF is over-expressed on many types of solid
cancer cells [8-10,13,14]. Thus, TF provides a common
but specific target in tumour neovasculature and tumour
cells for development of novel cancer therapies and
diagnostic protocols.
The Icon protein can specifically target both tumour
cells and tumour vascular endothelial cells via binding
TF for the treatment and diagnosis of cancer. The Icon
molecule is designed to bind to TF with far higher affi-
nity and specificity than can be achieved with an anti-
TF antibody. Icon has several important advantages as
compared to an anti-TF monoclonal antibody. The Kd
for fVII binding to TF is up to 10-12 M [21], in contrast
to anti-TF antibodies that have a Kd in the range of 10-
8 to 10-9 M for TF [22]. Icon is produced by recombi-
nant DNA technology, allowing mouse Icon (mouse
fVII/human IgG1 Fc) to be made and tested in animal
models of diseases and human Icon (human fVII/human
IgG1 Fc) to be made from human sources for future
clinical trials without the need of the humanisation pro-
cess that is required for monoclonal antibodies. Tests of
Icon immunotherapy in mouse models of primary and
metastatic tumours have demonstrated that primary and
distant metastatic tumours can be eradicated without
causing obvious toxicity [9,10,23]. In addition, Icon was
efficacious and safe for the eradication of choroidal neo-
vascularisation in mouse and pig models simulating wet-
form macular degeneration [24,25] and for eradication
of the neovasculature in human endometriosis in a
mouse model [26].
Recently we showed that peripheral blood lympho-
cytes could induce Icon-dependent cytotoxicity to
human endometrial cancer cells in vitro [27]. However,
the underlying killing mechanisms of Icon immunother-
apy remain to be further defined. The objective of this
study is to define these mechanisms of Icon immu-
notherapy for cancer in vitro and in vivo using a squa-
mous carcinoma human tongue cancer line TCA8113
[28]. Because Icon is an antibody-like molecule, presum-
ably natural killer (NK) cells and complement should be
separately involved in the killing actions through anti-
body-dependent cellular cytotoxicity (ADCC) and com-
plement dependent cytotoxicity (CDC) pathways. NK
cells are highly specialised lymphoid cells involved in
ADCC against tumour or virally infected cells. Here, we
test Icon-mediated ADCC and CDC effects on human
tongue cancer in vitro and in vivo in two genetically
modified SCID mouse strains [29], namely SCID/CB-17
and SCID/Beige. The SCID/CB-17 strain has functional
NK cells but lack mature B- and T-lymphocytes [30],
whereas the SCID/Beige strain not only lacks B-and
T-lymphocytes but also has defective NK cells [31,32].
Therefore, NK cell-mediated ADCC is only active in the
CB-17 strain, whereas both mouse strains have comple-
ment proteins that could mediate CDC. This paper
reports for the first time that Icon as an antibody-like
immunoconjugate containing human IgG1 Fc can initi-
ate NK cell-mediated ADCC for killing human cancer
cells in vitro and that NK cell level/activity is crucial for
the efficacy of Icon immunotherapy of human cancer
in vitro and in vivo.
Results
The mouse Icon protein can be produced by Icon
producer CHO cells and adenoviral vector-infected
tumour cells and can bind to human tongue cancer cells
As shown in SDS-PAGE (Figure 1a), the molecular
weight of mouse Icon (mfVII/hIgG1 Fc, GenBank acces-
sion no AF272773) produced by Icon producer CHO
cells was 210 kDa under non-reducing conditions,
and 105 kDa under reducing conditions with
b-mercaptoethanol. These results suggested that Icon is
a homodimeric molecule composed of two identical sin-
gle peptides, each with a molecular weight of 105 kDa.
Flow cytometry analysis showed that the Icon protein
could bind to human tongue cancer cells (Figure 1b).
Icon was also detected by Western-blotting in a
serum-free culture medium of human tongue cancer
TCA8113 cells after infection with an adenoviral vector
encoding GFP and Icon (AdmIcon), but not in the med-
ium of the cells infected with a control vector AdBlank
(Figure 1c). This result provides a link for understanding
the in vitro efficacy using Icon protein and the in vivo
efficacy using Icon vector, as reported below.
NK cells mediate Icon-ADCC on human tongue cancer
cells
The NK cells used in ADCC assays were isolated from
murine splenocytes of SCID/CB-17 mice using a rat
monoclonal anti-mouse NK cell DX5 antibody. DX5 anti-
body can bind to mouse NK cells without strain limita-
tion [33]. Before isolation, pan NK positive cells were
44.9% in splenocytes using a DX5-PE conjugate as deter-
mined by flow cytometry (Figure 2a). After isolation, the
NK percentage increased to 98.9% (Figure 2a). These
purified NK cells were used for Icon-ADCC below.
Using the Calcein-AM dye release assay, murine
splenic NK cells in the presence of mouse Icon protein
(10 μg/ml) killed 18% and 70% of human tongue can-
cer cells at effector:target (E:T) ratios of 1:1 and 10:1
respectively (Figure 2b) (two-tailed P = 0.0107 by
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unpaired t test). Note that the direct effect of NK cyto-
toxicity in the absence of Icon protein was subtracted
from these percentages of specific lysis. Thus, the
results suggested that mouse NK cells could mediate
mouse Icon, which contains a human IgG1 Fc as effec-
tor domain, for specific lysis of cancer cells through
ADCC mechanism.
Icon-CDC is less effective at killing human tongue cancer
cells than Icon-ADCC mediated by NK cells
We showed that the Icon-mediated CDC effect was
dependent upon the concentration of Icon protein (two-
tailed P < 0.05 for Icon protein at 5 μg/ml vs. 10 μg/ml
and 20 μg/ml and P = 0.534 for 10 μg/ml vs. 20 μg/ml
by unpaired t test) (Figure 2c). However, mouse Icon-
mediated CDC killed only about 33% specific lysis of the
cancer cells at 20 μg/ml and 25% at 10 μg/ml of Icon
protein (Figure 2c), which was less than that of Icon-NK
cell ADCC (Figure 2b) (70% specific lysis by NK cells
with 10 μg/ml Icon and E:T ratio of 10:1, P < 0.02 by
ANOVA single factor when Icon concentration was 10
μg/ml for CDC vs. ADCC). We conclude that Icon-NK
ADCC mediates a stronger killing effect than Icon-CDC
for TCA8113 cancer cells.
Figure 1 Production and binding activity of Icon protein. a. Molecular weight of the Icon protein produced by CHO cells analysed by SDS-
PAGE. fVII: mouse factor VII with K341A mutation; H: hinge region of a human IgG1 Fc; CH2 and CH3: the second and third domains of the
constant region on the heavy chain of a human IgG1 Fc. b. Binding activity of Icon protein to human tongue cancer TCA8113 cells by flow
cytometry. Control: TCA8113 cancer cells were not incubated with Icon but with secondary antibody FITC. Mouse Icon: the cells were incubated
with Icon protein then with the secondary antibody to human IgG Fc FITC. c. Immunoprecipitation Western-blotting analysis of Icon protein
production by TCA8113 cells one day after infection with AdmIcon (lane 1) or AdBlank (lane 2). The serum free culture medium from uninfected
TCA8113 cells was used as uninfected control (lane 3). M: Protein markers (Bio-Rad All blue). Molecular weights (kDa) of the protein markers are
indicated. Data are representative of two experiments.
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Icon protein has no direct effect on cancer cell
proliferation in the absence of NK cells and complement
We showed that Icon protein at various concentrations
ranging from 0.01 to 50 μg/ml, which was higher than
those in the ADCC and CDC experiments, did not have
any effects on the proliferation of TCA8113 cancer cells
(Figure 3). Thus we conclude that Icon has no direct
inhibitory effect on TF expressing cancer cell prolifera-
tion in the absence of immune cells and complement. In
another word, the killing effect observed in the ADCC
and CDC assays above was achieved by Icon in combi-
nation with NK (Figure 2b) or complement (Figure 2c)
but not by Icon alone (Figure 3).
NK cells are also the major players in vivo for Icon
immunotherapy of human tongue cancer in SCID mice
To test the role of NK cells in Icon immunotherapy in
vivo, the efficacy of Icon immunotherapy for human
tongue cancer was compared between the SCID/CB-17
(NK cell functional) and SCID/Beige (NK cell defective)
mouse strains.
Figure 2 Lysis of TCA8113 cancer cells by Icon-dependent NK cell-mediated ADCC and complement-mediated CDC in vitro. a. Isolation
of murine NK cells from a single cell suspension of splenocytes from SCID/CB-17 mice. b. Icon-dependent NK cell-mediated ADCC. c. Icon-
dependent complement-mediated cytotoxicity. Note that % specific lysis was derived from the % of cytotoxicity of Icon + NK cell or Icon +
complement subtracted by % of cytotoxicity of NK cell alone or complement alone. P values and no significance (ns) were analysed by unpaired
t test (b) or one way ANOVA with Tukey’s Multiple Comparison Test (c). Data are representative of two experiments.
Figure 3 Icon protein has no effect on cancer cell proliferation
in the absence of NK cell and complement. After incubation
with mouse Icon protein for 1 hr followed by overnight growth,
cancer cell proliferation was determined by CellTiter One Solution
reagent, as described in Methods. P values obtained were of no
significance as determined by one-way ANOVA with Tukey’s
Multiple Comparison Test. Data are representative of two
experiments.
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In SCID/CB-17mice (Figure 4a), TCA8113 tumours in
the control group (n = 3) grew rapidly and the mice had
to be euthanised on day 50 (tumour weights 8.29 ± 2.96
g on day 50, mean ± SD). In contrast, tumour volume
in the Icon treated mice (n = 4) decreased to 87% by
day 3 after the first injection of Icon vector and tumours
were completely eradicated in 2 of 4 Icon-treated mice
separately on day 60 and day 69. These mice were then
tumour free for the rest of experimental period (more
than 130 days) (Figure 4a). The other two Icon-treated
mice also initially responded to Icon treatment and their
tumours became necrotic, observed as ulcerations on
the tumours on day 12, even though the tumour size
was small (about 250 mm3). Tumour ulceration was not
observed in any control tumours even when the
tumours reached much larger volumes (9900 mm3), sug-
gesting that tumour ulceration, which occurred in all 4
treated mice, was a sign of the therapeutic effect of Icon
treatment and not due to spontaneous tumour necrosis.
However, tumours in the 2 partially responsive mice still
grew from the surrounding tumour margins on day 21
after the first series of injections. A second series of
injection with Icon vector was completed in these two
mice. Further Icon treatment caused bigger ulceration
but still did not eradicate tumours. Nevertheless, Icon-
treated tumour weights were 1.59 ± 1.98 g (mean ± SD)
on day 156, which were significantly smaller than those
of control tumours on day 50 (P = 0.015 by ANOVA
single factor).
In Beige mice (Figure 4b), tumour growth in the
Icon-treated mice (n = 5) was inhibited by Icon ther-
apy as compared to the control tumours (n = 5) (P <
0.01 on day 36 and < 0.001 on days 36-51 for AdmI-
con vs. AdBlank by two-way ANOVA). But by day 72,
tumours reached about 7800 mm3, a similar size to the
control tumours on day 51. The control mice had to
be euthanised on day 53 and the Icon-treated mice on
day 74. There was no significant difference in tumour
weights between control tumours (4.99 ± 2.11 g on
day 51) and Icon-treated (8.97 ± 4.06 g on day 74)
tumours (P = 0.110 by ANOVA single factor). Tumour
ulceration was not observed in any of control Beige
mice but was observed in one of 5 Icon-treated Beige
mice on day 51.
The results in these two SCID strains indicated that
Icon could completely eradicate human tongue tumours
in the CB17 strain that had functional NK cells, but did
not achieve the same effect in the Beige strain that did
not have functional NK cells, suggesting that NK cell
activity is crucial and responsible for Icon to completely
eradicate the established tumours. Assay for NK cell
percentage in the Icon-treated mice below further indi-
cated that not only the functional NK cells but also the
NK cell percentage in peripheral blood lymphocytes
(PBL) is crucial for Icon to completely eradiate tumour
in host mice. Taking these in vivo and in vitro results
together, we conclude that NK cell is the major player,
as compared to complement, in the Icon immunother-
apy for complete eradication of cancer.
All SCID mice were examined morphologically at the
end of the experiments. In CB-17 mice, enlarged spleens
were observed in all control mice and 2 Icon-treated PR
mice. The spleens were normal in the Icon-treated CR
mice. None of the CB-17 mice had metastatic tumours.
In Beige mice, enlarged spleens were observed in 3 of 5
control mice and 1 of 5 of the Icon-treated mice. One
Figure 4 NK cells are crucial for the efficacy of Icon
immunotherapy of human tongue cancer in vivo in SCID mice.
Human tongue tumour xenografts were generated separately in
SCID/CB-17 (a) and SCID/Beige mice (b) by subcutaneous injection
of the TCA8113 tumour cells into the right flank of each mouse.
After tumour formed, adenoviral vector encoding mouse Icon
(AdmIcon) or control vector (AdBlank) were injected intratumourally
with 1 × 1010 viral particles (vp) per injection for immunotherapy on
the days as indicated below. a: In CB-17 SCID mice, AdmIcon (◯, n
= 4) or AdBlank (Δ, n = 3) was injected on days 0, 3, 6, 9, 12, 15, 18,
21. Additional intratumoural injections of AdmIcon were
administered in 2 partially responded mice on days 54, 84, 93, 99
and 135. P < 0.001 on days 6 and 9 and < 0.001 on days 12-48 for
AdmIcon vs. AdBlank by two-way ANOVA. b: In Beige SCID mice,
AdmIcon (◯, n = 5) or AdBlank (Δ, n = 5) was intratumourally
injected on days 0, 3, 6, 9, 12, 15, 18, 21, 24, 27, 36 and 42. The
control mice were euthanised on day 53 and the Icon-treated mice
on day 74. P < 0.01 on day 36 and < 0.001 on days 39-51 by two-
way ANOVA for AdmIcon vs. AdBlank.
Hu and Li BMC Immunology 2010, 11:49
http://www.biomedcentral.com/1471-2172/11/49
Page 5 of 11
control Beige mouse had one metastatic nodule (2 mm
in diameter) in the lung and one Icon-treated Beige
mouse had 3 metastatic nodules (2 mm in diameter) in
the lungs. There were no other abnormalities observed
in the SCID mice.
NK cells can prevent tumour formation and their
percentages in PBL are closely correlated with the
efficacy of Icon-mediated immunotherapy in SCID mice
Using flow cytometry with an NK cell specific antibody
DX5-FITC conjugate, we analysed the NK cell percen-
tages in PBL from normal SCID/CB-17 and SCID/Beige
mouse strains. In female SCID/CB-17 mice, the NK per-
centage in PBL was 18.2 ± 5.2% at 4-weeks old (n = 9)
and 13.7 ± 5.3% at 9-10 weeks old (n = 10) with an
average of 16% at age of 4-10 weeks old (p = 0.0775
between 4 weeks old and 9-10 weeks old). In female
SCID/Beige mice, the NK percentage was 12.9 ± 1.1% at
4 weeks old (n = 3) (p = 0.116 as compared to the
CB-17 strain at age of 4 weeks old), indicating that NK
cells are present in peripheral blood of the Beige mouse
strain. However, it is notable that NK function was
depressed by Beige gene mutation [31,32].
To establish tumours for experiments in Figure 4a
and 4b, 10 SCID/CB-17 mice and 10 SCID/Beige mice
were separately injected s.c. with the same number (6 ×
105 cells) of human tongue cancer TCA8113 cells.
Within one month, all of 10 SCID/Beige mice evenly
developed tumours with an average of 270 mm3. How-
ever, it took 2 months for 4 of the 10 CB-17/SCID mice
to develop tumours with similar volume to the SCID/
Beige mice. Additionally, in this strain, another 3 had
tumours larger than those observed in the SCID/Beige
mice (1300 mm3) and the last 3 CB-17/SCID mice
never developed tumours. Similarly, in an unpublished
experiment there were another 10 SCID/CB-17 mice, 8
of which developed skin tumours early. The tumour
size also varied in these SCID/CB-17 mice. The differ-
ence in tumour growth between the CB-17 and Beige
SCID strains suggest that functional NK cells in the
CB-17 strain played a role in rejecting or delaying ton-
gue cancer formation.
To understand the variations in Icon efficacy between
the CR and PR SCID/CB-17 mice (Figure 4a), the NK
percentages in peripheral blood lymphocytes (PBL) were
monitored by flow cytometry 29 days before and at the
time of euthanisation. The Icon-treated CR mouse had a
normal NK cell percentage at 14.2% at 29 days before
enthanisation, whereas the NK level was 14.0% in a nor-
mal SCID/CB-17 mouse of the same age. However, the
NK level in the Icon-treated PR mouse was 9.6% at 29
days before euthanisation and further significantly
decreased to 3.7 ± 0.9% at the time of euthanisation. At
the same time, the CR mouse had 12.8 ± 2.0% of NK in
PBL (p < 0.03 by ANOVA single factor for CR mouse
vs. PR mouse), suggesting that an impaired NK level
could contribute to the faster tumour growth in 3 of the
CB-17/SCID mice above and to the resistance to Icon
immunotherapy observed in these PR mice (Figure 4a).
Discussion
We have previously shown that Icon immunotherapy
was efficacious for selective eradication of pathological
neovasculature for the treatment of several types of can-
cer [8-10,23], wet macular degeneration [24,25] and
endometriosis [26]. But its mechanism of action was
previously unclear. In this paper, we elucidate the
mechanisms of action of Icon immunotherapy for can-
cer in vitro and in vivo. We show that (i) both ADCC
and CDC are involved in mechanisms of action of Icon
immunotherapy, but NK cells play a more important
role than complement in mediating antibody-like Icon
immunoconjugate to kill cancer cells; and (ii) the activ-
ity and level of NK cells are crucial for Icon to comple-
tely eradicate cancer in mice. We have also ruled out
the possibility that Icon has any direct effects on killing
or inhibiting cancer cell proliferation. We understand
that the role of complement in mediating Icon immu-
notherapy can be further elucidated in complement-defi-
cient mice. However, so far these complement-deficient
mouse strains are derived from immunocompetent
mice, for example, C3-/-C4-/- was from C57Bl/6 back-
ground [34], in which human tumours cannot be gener-
ated. Therefore, further tests for the role of complement
in Icon immunotherapy will be completed using mouse
tumour cell lines in future studies.
NK cells played at least two distinct roles in this
study, the first being to prevent tumour development
after inoculation of tongue cancer cells by non-specific
killing and the other to mediate ADCC by Icon-guided
specific killing after Icon immunotherapy is initiated.
The first role of NK cells was observed as the difference
of tumour formation/volume between CB-17 and Beige
strains. Previous reports also showed that NK cells
could mediate ADCC for other therapeutic antibodies
including trastuzumab (Herceptin) for breast cancer
[35], rituximab (Rituxan) for B-cell lymphoma [36], and
Cetuximab for lung cancer [37].
It has been observed that NK cell percentage/activity
can be impaired by tumours in animals and cancer
patients. In 1979, Herberman RG et al. summarised in a
review article [38] that NK activity had been found to
be impaired in tumour-bearing mice and patients that
had large tumour loads. In later years, more reports
showed that the ADCC activity of NK cells was
impaired in patients with cancer, including breast [39],
gastric [40], esophageal [41,42], and urologic cancers
[43] as well as leukemia [44-46] and myeloma [47]. In
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addition, NK activity can decline with age [48], which
may contribute to higher incidence of cancer developed
in elderly populations. With regard to the role of NK
cells in Icon immunotherapy for tongue cancer, we
observed in this study that Icon immunotherapy was
able to completely eradicate tumours in SCID/CB-17
mice that had functional and normal levels of NK cells
but not in the Beige mice that did not have functional
NK cells. Icon was also unable to completely eradicate
tumours in some of the PR CB-17 mice in which NK
cell percentages were lower than the normal level (aver-
age 16% of PBL in 4-10 weeks old CB-17/SCID mice).
Considering the previous observations regarding
impaired NK cell activity in cancer patients and in mice,
as reviewed above, with our observations in this study,
we hypothesize that decreased/depressed NK cell level/
activity can contribute to resistance to Icon and other
antibody immunotherapies for cancer. Resistance to
antibody immunotherapy has been observed in preclini-
cal studies and clinical trials. For example, the rate of
primary resistance to single agent Her2-targeted trastu-
zumab immunotherapy was 66% to 88% of patients with
metastatic breast cancer that overexpressed the Her2
antigen [49]. Varchetta et al. analysed circulating mono-
nuclear cells in 18 breast cancer patients after treatment
of Her2 targeted-trastuzumab therapy and found that
NK cells and CD56+ T cells were involved in trastuzu-
mab treatment and concluded “quantity and lytic effi-
ciency of CD16+ lymphocytes [i.e., NK cells] are major
factors for ADCC induction by trastuzumab” [50].
If decreased NK cell level/activity is detected in host
(tumour-bearing mice or patients), Icon immunotherapy
should be combined with NK cell infusions and/or NK-
activating cytokines. Infusions of autologous or allor-
geneic NK cells for cancer therapy have been shown
feasible and well-torelated in cancer patients [51-53].
We will test if infusion of NK cells could amplify the
Icon efficacy in future preclinical and clinical studies. In
addition, efforts are being made in our laboratory in
generating immortalized NK cell lines. If successful,
these NK cell lines could be used for ADCC assays in
vitro and potentially for immunotherapy in vivo in com-
bination with Icon or other therapeutic antibodies.
Previous in vitro and in vivo studies have shown that
cytokines such as IL-2, IL-12, IL-15 and interferon can
enhance the effect of antibody-ADCC for immunother-
apy of cancer, e.g., IL-2 and IL-15 enhanced NK cell
response to Herceptin-coated Her2/neu+ breast cancer
cells in vitro [54]. Using an adenoviral vector encoding
mouse IL-12 in combination with AdmIcon vector, we
indeed observed that the efficacy of Icon immunother-
apy was significantly enhanced by mIL-12 for the treat-
ment of human tongue cancer in SCID/CB-17 mice and
murine breast cancer in Balb/c mice (Hu et al., unpub-
lished data).
In this regard, monitoring the NK level in PBL is
important for interpreting the efficacy of Icon and other
antibody immunotherapy. In this paper, we use a simple
flow cytometry procedure for this purpose, in which a
commercial anti-pan NK DX5 antibody FITC or PE
conjugate is first incubated with a small volume (100 μl)
of blood samples containing anti-coagulant such as
heparin or citrate sodium followed by lysis of RBC and
then cell sorting using flow cytometry. This procedure
can be easily adapted for clinical trials using anti-human
NK antibody fluorescent dye conjugates. We recom-
mend that NK level/activity should be monitored and
tested as a standard operation protocol in cancer
patients before and during the treatment with antibody
immunotherapy.
Conclusions
In conclusion, this paper reports for the first time the
efficacy and the mechanism of action of the novel, dual
neovasculature- and cancer cell-targeting fVII/Fc Icon
immunotherapy for human tongue cancer in vitro and in
vivo. The importance of NK cell level/activity for the
underlying mechanism of Icon immunotherapy could
also be true in the animal models of age-related macular
degeneration and endometriosis, in which Icon immu-
notherapy was effective in eradicating the pathological
neovasculature [24-26]. In addition, our observations on
the importance of NK cells can also have implications for
other immunotherapeutic antibodies that are currently
under investigation in preclinical and clinical studies.
Methods
Cell lines
Human tongue cancer TCA8113 cell is a squamous cell
carcinoma line derived from human tongue cancer [28]
and was kindly provided by Dr. Wei Guo at Shanghai
Medical University in China. TCA8113 and Chinese
Hamster Ovary (CHO) cells (ATCC) were grown in
RPMI 1640 supplemented with 10% FBS and antibiotics.
293 cells (ATCC), as adenoviral packaging cells, were
grown in DMEM with 10% FBS and antibiotics.
Construction of plasmid and synthesis of Icon (fVII/IgG1
Fc) protein
The expression plasmid DNA vector pcDNA3.1(+)
encoding murine fVII/hIgG1 Fc has been previously con-
structed and transfected into CHO cells to generate
stable Icon producer cell lines [8-10]. For Icon protein
production, the cloned Icon producer CHO cells were
first grown in serum containing RPMI 1640 medium.
When the cells reached approximately 85-90% con-
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fluency, they were switched to a serum-free Excell 301
medium (JRH Biosciences) supplemented with 1 μg/ml
vitamin K1 for g carboxyl posttranslational modification
to fVII protein [55]. The SFM medium was collected
twice a week and centrifuged. Affinity purification of
Icon protein was accomplished using Protein A [8] with
modifications as follows. After the SFM supernatant was
mixed with 1/50 volume of 1 M PB pH7.0 and filtered
through a 0.45 μm filter (Millipore), the supernatant was
loaded by pump at less than 5 ml/min speed to a 5-ml
HiTrap rProtein A column (Amersham Pharmacia) fol-
lowed by wash with 20 mM PB pH 7.0 and elution with
0.1 M Glycine-HCl pH2.8. The eluate was neutralised
immediately with 1/10 volume of 1 M Tris-HCl pH 9.0
and the fractions containing the Icon protein were com-
bined and dialysed against HEPES buffer (10 mM HEPES
pH7.0, 150 mM NaCl, 5 mM CalCl2) using a Slide-A-
Dialysis Cassette (Pierce). The molecular weights of the
monomer and dimer of the mfVII/hFc protein were
determined by SDS-PAGE. The binding activity of puri-
fied Icon protein was tested by fluorescence-activated cell
sorting (FACS) using human tongue cancer TCA8113
cells, following our earlier procedure [8-10].
Preparation of adenoviral vectors
The procedure of constructing the adenoviral shuttle
vector encoding the Icon and making the adenoviral
vector particles has been described previously [8] using
the AdEasy vector system with a modification to provide
dialysis of the vector. The Icon vector used in this study
separately encodes mouse Icon and green fluorescent
protein (GFP) (AdmIcon). The control vector encodes
GFP but does not encode Icon (AdBlank). Briefly, the
adenoviral vectors were first amplified in 293 cells and
were purified by CsCl gradient ultracentrifugation fol-
lowed by dialysis using a Slide-A-Dialysis Cassette
(Pierce, 3-12 ml) against 10 mM Tris-HCl pH 8.0, 2
mM MgCl2 and 4% sucrose, instead of PBS as previously
used, then aliquoted and stored at -80°C. The reason for
this modification was based on a report showing that
infectious activity of the adenoviral vector could be pre-
served longer in Tris buffer than in PBS [56].
Western blotting analysis of Icon in the culture medium
of tumour cells after infection with Adenoviral vector
encoding Icon
A similar procedure was described earlier [9]. The
human tongue cancer TCA8113 cells were grown in
RPMI 1640/10% FBS in a 6-well plate and then infected
with AdmIcon at 50 of multiplicity of infection by incu-
bation at 37°C for 90 min. After infection, the tumour
cells were washed and then were grown in serum free
medium supplemented with 1 μg/ml vitamin K1
(Sigma). The cells were observed and photographed
under fluorescent microscopy. The serum free culture
medium was tested for Icon protein production as fol-
lows. One ml supernatant of collected serum free cul-
ture medium was mixed with 1/50 volume of 1 M PB
pH7.4 and 10 μl of Protein A Plus resin (Pierce) at 4°C
overnight, and then the captured Icon protein on Pro-
tein A resin was eluted with 1 × SDS loading buffer and
analysed by SDS-PAGE and Western-blotting using 0.5
μg/ml of anti-human IgG Fc HRP conjugate (Vector
Laboratories) followed by ECL reagents (Pierce).
Isolation of murine splenic NK cells for ADCC assay
Mouse NK cells were isolated from splenocytes of 4-6
weeks old female CB-17/SCID mice by EasySep Murine
NK positive selection kit (Stem Cell Technologies) fol-
lowing the manufacturer’s instructions with modification
to remove red blood cells. To remove RBS, FACS lyso-
lution (150 mM NH4Cl, 1 mM KHCO3, 0.1 mM EDTA
pH 7.3) was added to the splenocyte single cell suspen-
sion with a ratio of 30:1 (FACSLysolution:Cell suspen-
sion) and incubated at RT for 30 min. After isolation,
100 μl of NK and non-NK cells were sorted by flow
cytometry to assure the purity.
Icon-mediated ADCC and CDC assays in vitro
Human tongue cancer TCA8113 cells were seeded into
U-bottom 96-well plates (1 × 104 cells per well) and
grown overnight. The following day, the cells were
washed 4 times with Hanks’ balanced salt solution
(HBSS) containing 5 mM of CaCl2 and were labeled
with Calcein-AM (Molecular Probe/Invitrogen) by incu-
bation to a final concentration of 8 μM Calcein-AM in
HBSS at 37°C for 40 min. After one wash, the cells were
incubated quadruplicate with mouse Icon protein or
HBSS buffer only at 37°C for 20 min. and the plates
were used for CDC or ADCC as follows.
For CDC assay, we used rabbit complement but not
human complement because it was reported that rabbit
serum had stronger complement activity than that from
several other species including humans [57]. 1:4 diluted
rabbit complement MA (Cedarlane Laboratories) in
HBSS was added to each well that had been incubated
with mouse Icon protein (Icon-CDC experimental wells)
or HBSS buffer (complement alone wells) and incubated
at 37°C for 60 min. For the ADCC assay, freshly isolated
mouse NK and non-NK cells were added to the plates
and incubated at 37°C for 4 hrs. In the NK cell alone
control wells, only the HBSS buffer was added without
Icon (in order to determine the direct effect of NK
cells). For both assays, only HBSS buffer was added
without Icon in the spontaneous release wells. In the
maximal release wells, 1/10 vol (10 μl) of 9% Triton-X
100 was added to HBSS to lyse the cells. Supernatant
from each well was transferred to a new 96-well plate
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and fluorescence was measured on a fluorescence
microplate reader (Bio-Tek) with excitation 485/20 nm
and emission 528/20 nm. The percent specific lysis of
cancer cells by Icon-CDC was calculated using the fol-
lowing formula: (Fluorescence in the experimental well-
Mean Fluorescence in the complement alone wells)/
(Mean Fluorescence in the maximal release wells-Mean
Fluorescence in the complement alone wells) × 100%.
Percent specific lysis of cancer cells by Icon-NK ADCC
was calculated with the following formula: (Fluorescence
in the Icon/NK cell well-Mean Fluorescence in the NK
cell alone wells)/(Mean Fluorescence in the maximal
release wells-Mean Fluorescence in the NK cell alone
wells) × 100%.
Cancer cell proliferation assay
Human tongue cancer TCA8113 cells were seeded at a
concentration of 2 × 104 cells per well in a 96 well plate
and grown in complete growth medium supplemented
with 10% heat inactivated FBS overnight. Then the can-
cer cells were incubated with mouse Icon protein diluted
in HBSS/1%BSA/10 mM CaCl2 at concentrations of 0,
0.01, 0.1, 1, 10, 20, or 50 μg/ml in quadruplicate at 37°C
for 1 hr. After removing the Icon solution, 100 μl of com-
plete growth medium was added to each well and the
cells were grown at 37°C and 5% CO2 overnight. 20 μl of
CellTiter One Solution (Promega) was added to each
experimental well and medium background control wells
and incubated at 37°C and 5% CO2. The medium back-
ground control contained growth medium without cells.
OD490 nm was measured separately at 4 hrs. The cell
proliferation percentage was calculated as (experimental
well-growth medium background control)/(no treatment
control-growth medium background control) × 100%.
Tumour xenograft models in mice
The protocol for the animal studies was approved by the
Yale University Institutional Animal Care & Use Com-
mittee. Human tongue tumour xenografts were sepa-
rately generated in 4-6 weeks old female SCID/CB-17
and SCID/Beige mice (Taconic Farms Inc.) by subcuta-
neous (s.c.) injection of 6 × 105 cells in 100 μl PBS.
Icon-mediated Immunotherapy for treatment of human
tongue tumours in SCID mice
After human tongue tumours formed under the skin of
SCID mice, the mice were injected intratumourally with
1 × 1010 viral particles per injection of an adenoviral vec-
tor encoding mouse Icon (AdmIcon), or a control vector,
AdBlank, which did not encode any therapeutic agent as
a blank vector control. The tumour volume (mm3) was
calculated by measuring two dimensions in millimeters
(mm) and using the formula (width)2 × length/2.
Flow cytometric analyses of NK cell percentage in mouse
peripheral blood lymphocytes
The NK cell percentage in peripheral blood lymphocytes
was determined by flow cytometry using anti-mouse NK
DX5-FITC conjugate (CALTAG). 100 to 200 μl of a
blood sample was taken by alternatively retro-orbital
blood sampling in mice with heparinised blood collect-
ing tubes (Chase Scientific) and mixed in tubes contain-
ing heparin (Sigma). Two μl of DX5 FITC conjugate
was added to each 100 μl of heparinised blood in a
15-ml tube and incubated on ice for 30 min. Red blood
cells were then lysed by adding 3 ml of FACS lysolution
into each tube and incubating at room temperature for
10 min. The leukocytes were spun down by centrifuga-
tion at 300 g for 3 min and were washed twice with 3
ml of FACS buffer (PBS pH7.4, 1% BSA, 0.05% NaN3)
and centrifuged at 300 g for 3 min. After the final wash,
cells were resuspended in 300 μl of PBS/2 μg/ml propi-
dium iodine (PBS/PI). The cells were sorted with BD
FACS machine. The percentage of fluorescent peak shift
was measured based on a control in which the DX5
FITC conjugate was not added and the result was pre-
sented as the NK cell percentage in peripheral blood
lymphocytes.
Statistical analysis
The data concerning the in vitro and in vivo effects of
Icon were presented as mean values ± standard devia-
tion and were analysed for significance between the
treated groups and the control groups by Prism 5 ver-
sion 5.0c (GraphPad Software Inc) and/or Microsoft
Excel using paired or unpaired t tests and one-way
ANOVA with Tukey’s Multiple Comparison Test or
two-way ANOVA methods. P values less than 0.05 were
considered statistically significant. For analyses of statis-
tical significance, quadruplicate wells in each group
were used for ADCC and CDC assays in vitro in tissue
culture plates and 5 mice per group were used in
in vivo animal studies unless specified.
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